NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $42.38 +0.20 (+0.47%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Supernus Pharmaceuticals Stock (NASDAQ:SUPN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SUPN alerts:Sign Up Key Stats Today's Range$41.88▼$43.1550-Day Range$41.28▼$49.0352-Week Range$40.51▼$59.68Volume738,469 shsAverage Volume610,146 shsMarket Capitalization$2.47 billionP/E RatioN/ADividend YieldN/APrice Target$62.83Consensus RatingHold Company Overview Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes. Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches. Its CNS portfolio also includes Qelbree (viloxazine extended-release), a non-stimulant treatment for ADHD in children and adults. The company has additionally pursued product candidates and commercial opportunities in areas such as Parkinson’s disease and other neurological disorders. Founded in 2005 and headquartered in Rockville, Maryland, Supernus primarily serves the U.S. pharmaceutical market through its commercial organization and distribution partners. The company was founded and is led by Jack A. Khattar, who serves as president and chief executive officer. Supernus continues to support its commercial products through research, development, and lifecycle-management activities aimed at expanding treatment options in CNS medicine.AI Generated. May Contain Errors. Read More Supernus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreSUPN MarketRank™: Supernus Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 188th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSupernus Pharmaceuticals has a consensus price target of $62.83, representing about 48.3% upside from its current price of $42.38.Amount of Analyst CoverageSupernus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth95.94% Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 95.94% in the coming year, from $1.97 to $3.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSupernus Pharmaceuticals has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Supernus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.37% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 8.65.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSupernus Pharmaceuticals has minimal institutional ownership at this time.Read more about Supernus Pharmaceuticals' insider trading history. Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUPN Stock News HeadlinesSupernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNSeptember 24, 2026 | businesswire.comAnalysts Set Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Price Target at $62.83September 23, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 2 at 1:00 AM | Profits Run (Ad)Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)September 20, 2026 | finance.yahoo.comWhy Did Supernus Pharmaceuticals (SUPN) Move Today?September 19, 2026 | finance.yahoo.comHow Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ OutlookSeptember 19, 2026 | finance.yahoo.comIndivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger ClosingSeptember 17, 2026 | quiverquant.comQSupernus Pharmaceuticals to Participate in September Investor ConferencesSeptember 2, 2026 | globenewswire.comSee More Headlines SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $49.70 at the beginning of the year. Since then, SUPN stock has decreased by 14.7% and is now trading at $42.38. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings results on Monday, August, 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by $1.43. The business's quarterly revenue was up 32.4% compared to the same quarter last year. Read the conference call transcript. When did Supernus Pharmaceuticals IPO? Supernus Pharmaceuticals (SUPN) raised $75 million in an initial public offering (IPO) on Tuesday, May 1st 2012. The company issued 5,769,000 shares at $12.00-$14.00 per share. Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' top institutional shareholders include Versant Capital Management Inc. Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola, Jonathan Rubin, Timothy C Dec and Bethany Sensenig. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings8/03/2026Today10/02/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, SUPN's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees778Year Founded2005Price Target and Rating Average Price Target for Supernus Pharmaceuticals$62.83 High Price Target$67.00 Low Price Target$55.00 Potential Upside/Downside+48.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E Ratio21.51 P/E Growth0.78Net Income-$38.55 million Net Margins-13.23% Pretax Margin-14.87% Return on Equity11.13% Return on Assets8.10% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio1.84 Sales & Book Value Annual Sales$718.95 million Price / Sales3.43 Cash Flow$3.79 per share Price / Cash Flow11.17 Book Value$18.52 per share Price / Book2.29Miscellaneous Outstanding Shares58,220,000Free Float53,275,000Market Cap$2.47 billion OptionableOptionable Beta0.55 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SUPN) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
